Marshall Wace’s Lipocine LPCN Stock Holding History

Marshall Wace’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25,921	Closed	-$353K	–	3596
2022 Q2	$353K	Sell	25,921 -7,177	-22%	-$112K	﹤0.01%	2958
2022 Q1	$771K	Buy	+33,098	New	+$693K	﹤0.01%	2564

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Marshall Wace's LPCN Position: Q3 2022 in Review

Marshall Wace sold out of Lipocine (LPCN) in Q3 2022, closing a stake of 25,921 shares — an estimated $353K sold.

Marshall Wace first reported a position in LPCN in Q1 2022 and held it in 2 quarters. The position peaked at $771K in Q1 2022. 46 funds tracked by Wall St. Rank hold LPCN as of Q3 2022.

Marshall Wace reported no remaining Lipocine position as of Q3 2022 after selling out during the quarter.
Marshall Wace sold 25,921 Lipocine shares in Q3 2022, an estimated $353K.
Marshall Wace first reported a position in Lipocine in Q1 2022 and held it in 2 quarters.
Marshall Wace's Lipocine position peaked at $771K in Q1 2022.
46 funds tracked by Wall St. Rank held Lipocine as of Q3 2022.

Based on Marshall Wace's 13F filing for Q3 2022, filed 14 Nov 2022.